Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

Basit Öğe Kaydı
dc.contributor.authorSaydam, Guray
dc.contributor.authorHaznedaroglu, Ibrahim Celalettin
dc.contributor.authorKaynar, Leylagul
dc.contributor.authorYavuz, Akif S.
dc.contributor.authorAli, Ridvan
dc.contributor.authorGuvenc, Birol
dc.contributor.authorAkay, Olga M.
dc.date.accessioned2024-04-24T17:07:47Z
dc.date.available2024-04-24T17:07:47Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: Nilotinib is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP). This study was the first prospective evaluation of the efficacy and safety of nilotinib in Turkish patients with newly diagnosed CML-CP. The primary endpoint of the study was the rate of major molecular response (MMR; BCR-ABL10.1% on the International Scale [BCR-ABL1(IS)]) by 12months.Methods: Patients with newly diagnosed CML-CP were treated with nilotinib 300mg twice daily. This analysis was based on the first 12months of follow-up in a 24-month study.Results and Conclusions: Of 112 patients enrolled, 66.1% (80% CI, 59.7-72.0%) achieved MMR and 22.3% achieved a deep molecular response of MR4.5 (BCR-ABL1(IS) 0.0032%) by 12months. During the first year of treatment, 1 patient progressed to blast crisis and 2 patients died. Safety results were consistent with previous studies. Most adverse events (AEs) were grade 1/2. Most frequently reported nonhematologic AEs of any grade were elevations in bilirubin, alanine aminotransferase, and triglycerides. These results support the use of nilotinib 300mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP.en_US
dc.description.sponsorshipNovartis Pharmaceuticals Corporationen_US
dc.description.sponsorshipThis study was funded by Novartis Pharmaceuticals Corporation.en_US
dc.identifier.doi10.1080/14656566.2016.1219338
dc.identifier.endpage1858en_US
dc.identifier.issn1465-6566
dc.identifier.issn1744-7666
dc.identifier.issue14en_US
dc.identifier.pmid27501474
dc.identifier.scopus2-s2.0-84982311617
dc.identifier.scopusqualityQ2
dc.identifier.startpage1851en_US
dc.identifier.urihttps://doi.org/10.1080/14656566.2016.1219338
dc.identifier.urihttps://hdl.handle.net/11468/16983
dc.identifier.volume17en_US
dc.identifier.wosWOS:000384401200003
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Opinion on Pharmacotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBcr-Abl1en_US
dc.subjectChronic Myeloid Leukemiaen_US
dc.subjectMolecular Responseen_US
dc.subjectNilotiniben_US
dc.subjectTyrosine Kinase Inhibitoren_US
dc.titleOutcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phaseen_US
dc.titleOutcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu